The science of sleep is in early stages of development, and the biochemical consequences of obstructive sleep apnea (OSA) are slowly being identified. Only recently have investigators begun to identify the commonalities and interaction between OSA and insulin resistance, the underlying pathology of type 2 diabetes. Obesity and increasing age play important parts in the natural history of both conditions, which frequently coexist. The purpose of this article is, first, to examine the extent and strength of studies that have investigated the association between OSA and increased insulin resistance or type 2 diabetes and, second, to propose a model that explains the association and cyclical interaction between OSA, obesity, and insulin resistance.
Get full access to this article
View all access options for this article.
References
1.
Al-Delaimy WK, Manson JE, Willett WC, Stampfer MJ, Hu FB. 2002. Snoring as a risk factor for Type II diabetes mellitus: a prospective study. Am J Epidemiol155(5):387-393.
2.
American Diabetes Association. 1998. Consensus development conference on insulin resistance. Diabetic Care21:310-317.
3.
American Diabetes Association. 1999. Tests of glycemia in diabetes. Diabetic Care22(suppl 1):77-79.
4.
American Diabetes Association. 2000a. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care23:S4-S19.
5.
American Diabetes Association. 2000b. Screening for type 2 diabetes. Diabetic Care23(suppl 1):20-23.
6.
American Diabetic Association. 1998. Consensus development conference on insulin resistance. Unpublished manuscript.
7.
American Heart Association. 1999. Diabetes mellitus: a major risk factor for cardiovascular disease. A joint editorial statement by the American Diabetes Association; the National Heart, Lung, and Blood Institute; the Juvenile Diabetes Foundation International; the National Institute of Diabetes and Digestive and Kidney Diseases; and the American Heart Association. Circulation100:1132-1143.
8.
Bjorntorp P. 1991. Metabolic implications of body fat distribution. Diabetic Care14:1132-1143.
9.
Bliwise DL, Feldman DE, Bliwise NG, Carskadon MA, Kraemen HC, North CS, Petta DE, Seidel WF, Dement WC. 1987. Risk factors for sleep disordered breathing in heterogeneous geriatric populations. J Am Geriatr Soc35:132-141.
10.
Brooks B, Cistulli PA, Borkman M, Ross G, McGhee S, Grunstein RR, Sullivan CE, Yue DK. 1994. Obstructive sleep apnea in obese noninsulin-dependent diabetic patients: effect of continuous positive airway pressure treatment on insulin responsive-ness. J Clin Endocrinol Metab79:1681-1685.
11.
Carlson JT, Hedner J, Elam M, Ejnell H, Sellgren J, Wallin BG. 1993. Augmented resting sympathetic activity in awake patients with obstructive sleep apnea. Chest103:1763-1768.
12.
Cooper BG, White JE, Ashworth LA, Alberti KG, Gibson GJ. 1995. Hormonal and metabolic profiles in subjects with obstructive sleep apnea syndrome and the acute effects of nasal continuous positive airway pressure (CPAP) treatment. Sleep18(3):172-179.
13.
Davies JJ, Turner R, Crosby J, Stradling JR. 1994. Plasma insulin and lipid levels in untreated obstructive sleep apnea: their comparison with matched controls and response to treatment. J Sleep Res3:180-185.
14.
Dimsdale JE, Coy TV, Ancoli-Israel S, Mills J, Clausen J, Ziegler MG. 1997. Sympathetic nervous system alterations in sleep apnea: the relative importance of respiratory disturbance, hypoxia, and sleep quality. Chest111:639-642.
15.
Dimsdale JE, Coy TV, Ziegler MG, Ancoli-Israel S, Clausen J. 1995. The effect of sleep apnea on plasma and urinary catechol-amines. Sleep18:317-331.
16.
Elmasry A, Lindberg E, Berne C, Janson C, Gislason T, Tageldin MA, Boman G. 2001. Sleep-disordered breathing and glucose metabolism in hypertensive men: a population-based study. J Intern Med249:153-161.
17.
Facchini FS, Stoohs RA, Reaven GM. 1996. Enhanced sympathetic nervous system activity: the linchpin between insulin resistance, hyperinsulinemia, and heart rate. Am J Hypertens9:1013-1017.
18.
Fletcher EC. 1997. Sympathetic activity and blood pressure in the sleep apnea syndrome. Respiration64:22-28.
19.
Gislason T, Almovist M. 1987. Somatic diseases and sleep com-plaints. Acta Med Scandinvia221:475-481.
20.
Gonzalez-Ortiz M, Martinez-Abundis E, Balcazar-Munoz BR, Pascoe-Gonales S. 2000. Effect of sleep deprivation on insulin sensitivity and cortisol concentration in healthy subjects. Diabetes Nutr Metab13:80-83.
21.
Greenberg HE, Sica A, Batson D, Scharf SS. 1999. Chronic intermittent hypoxia increases sympathetic responsiveness to hypoxia and hypercapnia. J Applied Physiol86:298-305.
22.
Grunstein RR. 1996. Metabolic aspects of sleep apnea. Sleep19(suppl.):218-220.
23.
Grunstein RR. 2000. Endocrine disorders. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 3rd ed. Philadelphia: W. B. Saunders. p 1103-1112.
24.
Grunstein RR, Stenlof K, Hedner J, Sjostrom L. 1995. Impact of obstructive sleep apnea and sleepiness on metabolic and cardiovascular risk factors in the Swedish Obese Subjects (SOS) study. Int J Obesity19:410-418.
25.
Guilleminault C, Dement WC, editors. 1978. Sleep apnea syndromes and related disorders. In: Sleep apnea syndromes. New York: Wiley. p 120-131.
26.
Guyton AC, Hall JE. 1996. Textbook of medical physiology. 9th ed. Philadelphia: W. B. Saunders.
27.
He J, Kryger MH, Zorick FJ, Conway W, Roth T. 1988. Mortality and apnea index in obstructive sleep apnea: experience in 385 male patients. Chest94:914.
28.
Hedner J, Darpo B, Ejnell H, Carlson J, Caidahl K. 1995. Reduction in sympathetic activity after long-term CPAP treatment in sleep apnoea: cardiovascular implications. Eur Res Journal8:222-229.
29.
Hedner J, Ejnell H, Sellgren J, Hedner T, Wallin G. 1988. Is high and fluctuating muscle nerve sympathetic activity in the sleep apnoea syndrome of pathogentic importance for the development of hypertension? J Hypertens6(suppl 4):S529-S531.
30.
Horner RL, Brooks D, Kozar LF, Tse S, Phillipson EA. 1995. Immediate effects of arousal from sleep on cardiac autonomic outflow in the absence of breathing in dogs. J Appl Physiol79(1):151-162.
31.
Hudgel DW, Gordon EA. 1997. Serotonin-induced cortisol release in CPAP-treated obstructive apnea patients. Chest111:632-638.
32.
Ip MS, Lam B, Ng MM, Lam WK, Tsang KW, Lam KS. 2002. Obstructive sleep apnea is independently associated with insulin resistance. Am J Respir Crit Care Med165(5):670-676.
33.
Julius S, Gudbrandsson T. 1992. Early association of sympathetic overactivity, hypertension, insulin resistance, and coronary risk. J Cardiovasc Pharmacol20(suppl):40-48.
34.
Katsumata K, Okada T, Miyao M, Katsumata Y. 1991. High incidence of sleep apnea syndrome in a male diabetic population. Diabetic Res Clin Prac13:45-52.
35.
Kiley JP, Edilman N, Derderian S, Horan M, Littner M. 1994. Cardiopulmonary disorders of sleep. In: National Commission of Sleep Disorders Research, editor, Wake up America: a national sleep alert. Bethesda, MD: National Institute on Aging. p. 10-74.
36.
Loredo JS, Ziegler MG, Ancoli-Israel S, Clausen JL, Dimsdale JE. 1999. Relationship of arousals from sleep to sympathetic nervous system activity and BP in obstructive sleep apnea. Chest116(3):655-659.
37.
Moan A, Nordby G, Rostrup M, Eide I, Kjeldsen SE. 1995. Insulin sensitivity, sympathetic activity, and cardiovascular reactivity in young men. Am J Hypertens8:268-275.
38.
Narkiewicz K, Van de Borne PJ, Cooley RL, Dyken ME, Somers VK. 1998. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation98:772-776.
Newman AB, Nieto FJ, Guidry U, Lind BK, Redline S, Pickering TG, Quan SF. 2001. Relation of sleep-disordered breathing to cardiovascular disease risk factors: the Sleep Heart Health Study. Am J Epidemiol154(1):50-59.
41.
Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agnostino RB, Newman AB, Lebowitz MD, Pickering TG. 2000. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. JAMA283:1829-1836.
42.
Partinen M, Guilleminault C. 1990. Daytime sleepiness and vascular morbidity at seven-year follow-up in obstructive sleep apnea patients. Chest97:27-32.
43.
Pouliot M, Despres J, Nadeau A, Moorjani S, Prudhomme D, Lupien PJ, Tremblay A, Bouchard C. 1992. Visceral obesity in men: associations with glucose tolerance, plasma insulin, and lipoprotein levels. Diabetes41:826-834.
44.
Punjabi NM, Sorkin JD, Katzel LI, Goldberg AP, Schwartz AR, Smith PL. 2002. Sleep-disordered breathing and insulin resistance in middle-aged and overweight men. Am J Respir Crit Care Med165(5):677-682.
45.
Reaven GM. 1988. Role of insulin resistance in human disease. Diabetes37:1595-1607.
46.
Redline S, Adams N, Strauss ME, Roebuck T, Winters M, Rosen-berg C. 1998. Improvement of mild sleep-disordered breathing with CPAP compared with conservative therapy. Am J Res Crit Care Med157:858-865.
47.
Rosenow F, McCarthy V, Caruso C. 1998. Sleep apnoea in endocrine disease. J Sleep Res7:3-11.
48.
Saarelainen S, Lehtela J, Kallonen E. 1997. Effect of nasal CPAP treatment on insulin sensitivity and plasma leptin. J Sleep Res6:146-147.
49.
Saini J, Krieger J, Brandenberger G, Wittersheim G, Simon C, Follenus M. 1993. Continuous positive airway pressure treatment: effects on growth hormone, insulin and glucose profiles in obstructive sleep apnea patients. Hormone Metab Res25:375-381.
50.
Selye H. 1956. The stress of life. New York: McGraw-Hill.
51.
Smith ML, Niedermaier ON, Hardy SM, Decker MJ, Strohl KP. 1996. Role of hypoxemia in sleep apnea-induced sympathoexcitation. J Autonom Nerv Sys56(3):184-190.
Supiano MA, Hogikyan RV, Morrow LA, Ortiz-Alonso FJ, Herman WH, Bergman RN, Halter JB. 1992. Hypertension and insulin resistance: role of sympathetic nervous system activity. Am J Physiol263:E935-E942.
58.
Tiihonen M, Partinen M, Narvanen S. 1993. The severity of obstructive sleep apnoea is associated with insulin resistance. J Sleep Res2:56-61.
59.
Vgontzas AN, Papanicolaou DA, Bixler EO, Hopper K, Lotsikas A, Lin H, Kales A, Chrousos GP. 2000. Sleep apnea and day-time sleepiness and fatigue: relation to visceral obesity, insulin resistance, and hypercytokinemia. J Clin Endocrinol Metab85:1151-1158.
60.
Waradekar NV, Sinoway L, Zwillich CW, Leuenberger UA. 1996. Influence of treatment on muscle sympathetic nerve activity in sleep apnea. Am J Res Crit Care Med153:1333-1338.
61.
Wilcox I, McNamara SG, Collins FL, Grunstein RR, Sullivan CE. 1998. “Syndrome Z”: the interaction of sleep apnoea, vascular risk factors and heart disease. Thorax53:S25-S28.
62.
Young T, Peppard P. 2000. Sleep-disordered breathing and cardio-vascular disease: epidemiologic evidence for a relationship. Sleep23(suppl 4):S122-S126.
63.
Ziegler MG, Loredo JS, Ancoli-Israel S, Dimsdale JE. 2001. Effect of continuous positive airway pressure and placebo treatment on sympathetic nervous activity in patients with obstructive sleep apnea. Chest120(3):887-893.
